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Granulocytic sarcoma (GS) is a rare extramedullary tumor composed of immature myeloid cells. It is usually associated with
leukemia or other myeloproliferative disorders. It occurs very rarely without overt hematologic diseases. A 19-year-old man
presented with left knee mass. Biopsy with pathological analysis showed lymphoma aspect. Immunostains yielded the diagnosis of
GS with myeloperoxidase and CD43 positivity. There was no systemic manifestation of leukemia, and bone marrow biopsiy was
negative for neoplastic inﬁltration. Chemotherapy by CHOP was eﬃcient, and the patient remaind alive and healthy 40 months
after the end of treatment. The case is discussed in the framework of the existing literature about the diagnosis, treatment, and
prognosis of this very rare condition.
1.Background
Granulocytic sarcoma (GS) is a rare localized tumor com-
posed of immature granulocytic precursors. These neo-
plasms are known as monocytic sarcoma and chloroma
which refers to the green coloration of some of these tumors
on gross examination [1]. It is usually associated with
leukemia or other myeloproliferative disorders [2]. However,
it occurs very rarely without hematologic diseases [3], and
the diagnosis is diﬃcult in such cases.
The most common sites of involvement are the skin,
lymph nodes, soft tissues, and bone, but the tumor can occur
virtually anywhere [2–6]. Although nonleukemic GS may be
found in any location, primary occurrence in the knee is
exceptional. Here we report a very rare case of GS of the knee
but no bone marrow involvement at presentation which was
accurately diagnosed and has been followed up for a long
period.
2.CaseReport
A 19-year-old Berber Moroccan man began experiencing
pain in his left knee. His medical history was otherwise
unremarkable. Physical examination revealed no abnormal-
ity except for an 8cm, mobile mass of left knee with no
involvement of overlying skin. CTscan revealed a large mass
of anterior left knee involving bone and soft tissue suspicious
of sarcoma (Figure 1). A radionuclide bone scan showed a
single area of uptake of radiotracer in the left knee.
Biopsy showed a green colour of the tumour, and
pathological analysis revealed diﬀuse proliferation of round
cells with medium-sized or large nuclei lymphoma aspect.
ImmunostainsshowedmyeloperoxidaseandCD43positivity
and leukocyte common antigen (LCA) and CD 3, 5, 56
negativity indicating a diagnosis of a well-diﬀerentiated
granulocytic sarcoma. There was no systemic manifesta-
tion of leukemia. The blood cell count, thoracoabdominal
CTscan, and bone marrow histology were normal.
The patient received 6 cycles of chemotherapy by CHOP
(consisting of 750mg/m2 cyclophosphamide intravenously
injected on day 1, 50mg/m2 doxorubicin injected intra-
venously, on day 1; 1.4mg/m2 vincristine intravenously
injected on day 1, and 100mg prednisolone orally admin-
istrated on days 1–5 repeated every three weeks). The patient
respondedwelltothetreatment,andcompleteremissionwas
achieved. He remained alive and healthy 40 months after the
e n do ft r e a t m e n t .
3. Discussion
GS is a rare extramedullary tumor that consists of immature
granulocytic cells. this tumor was ﬁrst described in 1811 and2 Case Reports in Medicine
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Figure 1: A large mass of anterior left knee involving bone and soft tissue.
originally called chloroma by King in 1853 [7]. The term
“chloroma” is derived from the Greek word chloros (green).
The estimated incidence is about 0,7 per million in children
and 2 per million in adults [8]. There is no sex predilection,
withameanageof48years(range:2–81)[1].GSoccursmost
commonly in bone, periosteum, soft tissue, lymph nodes,
and skin, although it can occur anywhere throughout the
body [9].
GS usually presents concomitantly with or after the onset
of acute myelogenous leukemia, blastic phase of chronic
myelogenous leukemia, or myelodysplastic syndrome [9].
However, it is seen very rarely without bone marrow disease
as in our case and symptoms are secondary to the mass eﬀect
of the tumor. To the best of our knowledge, there has been
only one case report of nonleukemic GS of the knee in the
medical literature [10].
Macroscopically, GS is usually green in appearance. The
green color, which is due to the presence of myeloperoxidase
(MPO) in the leukemia cells, is not present in all tumors of
t h i st y p e[ 11]. According to the World Health Organization
classiﬁcation, the tumor is histologically classiﬁed into 3
types: well-diﬀerentiated, poorly diﬀerentiated, and blastic
[12, 13]. The diagnosis is often diﬃcult in GS cases when
the myeloblastic cells are poorly diﬀerentiated and the tumor
lacksthecharacteristicgreencolor.Alargeproportion(75%–
86%) of GS in nonleukemic patients is initially misdiag-
nosed and frequentlymistaken for non-Hodgkin lymphoma,
small round cell tumor (neuroblastoma, rhabdomyosar-
coma, Ewing sarcoma/PNET, and medulloblastoma), and
undiﬀerentiated carcinoma [8]. In such isolated presen-
tation, early diagnosis is based on immunohistochemical
analysis, especially staining of MPO and CD43. Traweek et
al. suggested that an immunohistochemical panel including
CD20, CD43, CD68, and MPO can successfully identify 96%
of extramedullary myeloid cell tumors via paraﬃns e c t i o n s
[13].
The rarity of cases of nonleukemic GS has limited the
availability of prospective studies on the eﬀectiveness of
various treatment strategies. Although no standard treat-
ment protocol has been established, several previous reports
suggested that local treatments such as surgical excision
and/orradiationtherapyalonewouldnotbesuﬃcientforthe
treatment of nonleukemic GS [1, 2, 14] and early aggressive
chemotherapy may represent the best chance for remission
[14–17]. Our patient received 6 cycles of CHOP-regimen
because he refused bone marrow transplantation.
The long-term prognosis of nonleukemic GS remains
poor [15], and the majority of these patients die of leukemia
within an average of 16.5 months after diagnosis [9].
Uncommonly, however, cases of no progression have also
been reported [18, 19]. In our case, the patient has remained
free of disease for 40 months.
GS is rare, and clinical diagnosis is especially diﬃcult
without bone marrow involvement. Immunohistochemical
studies using an appropriate panel of markers are extremely
helpful to make a correct diagnosis. The strategy for the
management of nonleukemic GS should be individualized.
Aggressive chemotherapy is beneﬁcial and may induce
complete remission. Early diagnosis and strict followup of
these patients are essential for a better outcome in GS.
Consent
Written informed consent was obtained from the patient’s
father for publication of this case report. A copy of the
written consent is available for review with the Editor-in-
Chief of this journal.
Conﬂict of interests
The authors declare that they have no conﬂict of interestsCase Reports in Medicine 3
Authors’ Contributions
I. Elghissassi conceived the case report, analyzed and inter-
preted the patient data regarding the haematological disease
H. Innrhaoun analyzed and interpreted the patient data and
was a major contributor in the literature review H. Mrabti
analyzed and interpreted the patient data and was a major
contributor in the literature review H. Errihani contributed
torevision,supervisionandapprovalofthework.Allauthors
read and approved the ﬁnal manuscript.
Abbreviations
GS: Granulocytic sarcoma
CD: Cluster of diﬀerentiation
CHOP: Cyclophosphamide, doxorubicin,
vincristine and prednisolone
LCA: Leukocyte common antigen
MPO: Myeloperoxidase
PNET: Primitive neuroectodermal tumor.
References
[1] R. S. Neiman, M. Barcos, C. Berard et al., “Granulocytic
sarcoma: a clinicopathologic study of 61 biopsied cases,”
Cancer, vol. 48, no. 6, pp. 1426–1437, 1981.
[2] J. M. Meis, J. J. Butler, B. M. Osborne, and J. T. Manning,
“Granulocytic sarcoma in nonleukemic patients,” Cancer, vol.
58, no. 12, pp. 2697–2709, 1986.
[3] D. Antic, S. Verstovsek, I. Elezovic et al., “Spinal epidural
granulocytic sarcoma in non-leukemic patient,” International
Journal of Hematology, vol. 89, no. 1, pp. 95–97, 2009.
[4] A. Quintas-Cardama, M. Fraga, J. Antunez, and J. Forteza,
“Primary extramedullary myeloid tumor of the breast: a case
report and review of the literature,” Annals of Hematology, vol.
82, no. 7, pp. 431–434, 2003.
[5] Y.Rong,D.Wang,W.Lou,T.Kuang,andD.Jin,“Granulocytic
sarcoma of the pancreas: a case report and review of the
literatures,” BMC Gastroenterology, vol. 10, article 80, 2010.
[6] Y. Manabe, Y. Hamakawa, K. Sunami, Y. Ohta, N. Omori,
and K. Abe, “Granulocytic sarcoma with orbit, caude equina,
muscle and peripheral nerve extension but without bone
marrow involvement,” Internal Medicine, vol. 46, no. 9, pp.
633–635, 2007.
[7] A. King, “A case of chloroma,” Monthly Journal of the Medical
Society, vol. 17, article 97, 1853.
[8] L.P.Menasce,S.S.Banerjee,E.Beckett,andM.Harris,“Extra-
medullary myeloid tumour (Granulocytic sarcoma) is often
misdiagnosed: a study of 26 cases,” Histopathology, vol. 34, no.
5, pp. 391–398, 1999.
[9] S. Paydas, S. Zorludemir, and M. Ergin, “Granulocytic sar-
coma: 32 cases and review of the literature,” Leukemia and
Lymphoma, vol. 47, no. 12, pp. 2527–2541, 2006.
[10] C. Powers, K. G. Beavis, and B. J. Richmond, “Lytic lesion of
the knee in a 27-year-old man,” Cleveland Clinic Journal of
Medicine, vol. 58, no. 6, pp. 471–474, 1991.
[11] S.Ugras,B.Cirak,M.Karakok,andB.Guven,“Spinalepidural
granulocytic sarcoma (chloroma) in a non-leukemic child,”
Pediatrics International, vol. 43, no. 5, pp. 505–507, 2001.
[12] Y. H. Liu, H. G. Zhuang, X. B. Liao, X. L. Luo, X. L. Cai, and D.
L. Luo, “Diagnosis and diﬀerential diagnosis of granulocytic
sarcomas,” Chinese Journal of Hematology, vol. 24, no. 11, pp.
568–571, 2003.
[13] S. T. Traweek, D. A. Arber, H. Rappaport, and R. K. Brynes,
“Extramedullary myeloid cell tumors: an immunohistochem-
ical and morphologic study of 28 cases,” American Journal of
Surgical Pathology, vol. 17, no. 10, pp. 1011–1019, 1993.
[14] S. C. H. Kim, S. Natarajan-Ame, B. Lioure et al., “Successful
treatment of a granulocytic sarcoma of the uterine cervix in
completeremissionatsix-yearfollow-up,”JournalofOncology,
vol. 2010, Article ID 812424, 3 pages, 2010.
[15] T. Y. Lan, D. T. Lin, H. F. Tien, R. S. Yang, C. Y. Chen, and
K. Wu, “Prognostic factors of treatment outcomes in patients
with granulocytic sarcoma,” Acta Haematologica, vol. 122, no.
4, pp. 238–246, 2009.
[16] K. Yamauchi and M. Yasuda, “Comparison in treatments of
nonleukemic granulocytic sarcoma: report of two cases and a
review of 72 cases in the literature,” Cancer, vol. 94, no. 6, pp.
1739–1746, 2002.
[17] A. M. Tsimberidou, H. M. Kantarjian, S. Wen et al., “Myeloid
sarcoma is associated with superior event-free survival and
overall survival compared with acute myeloid leukemia,”
Cancer, vol. 113, no. 6, pp. 1370–1378, 2008.
[18] A. Rodr´ ıguez P´ erez, M. C. L´ opez Carrizosa, L. Villal´ on Blanco,
P. M. Samper Ots, and E. Ortiz Cruz, “Granulocytic sarcoma
of the right humerus in a non-leukaemia patient,” Clinical &
Translational Oncology, vol. 10, no. 11, pp. 758–760, 2008.
[19] W. K. Hyun, S. J. Choi, J. H. Lee et al., “Nonleukemic
granulocytic sarcoma in the bile duct: a case report,” Journal
of Korean Medical Science, vol. 21, no. 4, pp. 745–748, 2006.